ClinicalTrials.gov
ClinicalTrials.gov Menu

NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03399448
Recruitment Status : Recruiting
First Posted : January 16, 2018
Last Update Posted : June 20, 2018
Sponsor:
Information provided by (Responsible Party):
University of Pennsylvania

Brief Summary:
This is a first-in-human trial proposed to test HLA-A*0201 restricted NY-ESO-1 redirected T cells with edited endogenous T cell receptor and PD-1.

Condition or disease Intervention/treatment Phase
Multiple Myeloma Melanoma Synovial Sarcoma Myxoid/Round Cell Liposarcoma Biological: NY-ESO-1 redirected autologous T cells with CRISPR edited endogenous TCR and PD-1 Drug: Cyclophosphamide Drug: Fludarabine Device: NY-ESO-1 expression testing Phase 1

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 18 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Phase 1 Trial of Autologous T Cells Engineered to Express NY-ESO-1 TCR and CRISPR Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T Cells)
Estimated Study Start Date : June 2018
Estimated Primary Completion Date : January 2033
Estimated Study Completion Date : January 2033


Arm Intervention/treatment
Experimental: Multiple Myeloma (MM) Biological: NY-ESO-1 redirected autologous T cells with CRISPR edited endogenous TCR and PD-1
Autologous T cells transduced with a lentiviral vector to express NY-ESO-1 and electroporated with CRISPR guide RNA to disrupt expression of endogenous TCRα, TCRβ and PD-1 (NYCE T Cells).

Drug: Cyclophosphamide
a cytotoxic chemotherapy agent used for lymphodepletion prior to NYCE T cells.

Drug: Fludarabine
a chemotherapy agent used for lymphodepletion prior to NYCE T cells.

Device: NY-ESO-1 expression testing
Testing to determine if NY-ESO-1 is expressed on tumor tissue.

Experimental: Synovial Sarcoma (SS) and Myxoid/Round Cell Liposarcoma (MRCL) Biological: NY-ESO-1 redirected autologous T cells with CRISPR edited endogenous TCR and PD-1
Autologous T cells transduced with a lentiviral vector to express NY-ESO-1 and electroporated with CRISPR guide RNA to disrupt expression of endogenous TCRα, TCRβ and PD-1 (NYCE T Cells).

Drug: Cyclophosphamide
a cytotoxic chemotherapy agent used for lymphodepletion prior to NYCE T cells.

Drug: Fludarabine
a chemotherapy agent used for lymphodepletion prior to NYCE T cells.

Device: NY-ESO-1 expression testing
Testing to determine if NY-ESO-1 is expressed on tumor tissue.

Experimental: Melanoma
Not Recruiting at the UPenn Site
Biological: NY-ESO-1 redirected autologous T cells with CRISPR edited endogenous TCR and PD-1
Autologous T cells transduced with a lentiviral vector to express NY-ESO-1 and electroporated with CRISPR guide RNA to disrupt expression of endogenous TCRα, TCRβ and PD-1 (NYCE T Cells).

Drug: Cyclophosphamide
a cytotoxic chemotherapy agent used for lymphodepletion prior to NYCE T cells.

Drug: Fludarabine
a chemotherapy agent used for lymphodepletion prior to NYCE T cells.

Device: NY-ESO-1 expression testing
Testing to determine if NY-ESO-1 is expressed on tumor tissue.




Primary Outcome Measures :
  1. Determine safety profile of a single infusion of NYCE T cells by monitoring the frequency and severity of adverse events assessed by the National Cancer Institute (NCI) - Common Toxicity Criteria (v4.03) [ Time Frame: 5 years ]
  2. Evaluate Manufacturing Feasibility of NYCE T Cells. [ Time Frame: 5 years ]
    Evaluate the percentage of manufacturing products that do not meet release criteria for vector transduction efficiency, gene disruption T cell product purity, viability, sterility or due to tumor contamination.


Secondary Outcome Measures :
  1. Percentage of patients achieving complete response (CR) before or at Month 6 [ Time Frame: 4 years ]
  2. Overall survival (OS) [ Time Frame: 5 years ]
  3. Duration of remission (DOR) [ Time Frame: 5 years ]
  4. Progression- free survival (PFS) [ Time Frame: 5 years ]
  5. Cause of death (COD) when appropriate [ Time Frame: 5 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

- 1. Subjects with a confirmed diagnosis of relapsed refractory multiple myeloma (MM), melanoma, synovial sarcoma, or myxoid/round cell liposarcoma (MRCL) as follows:

a. Multiple Myeloma i. Subjects must have a confirmed prior diagnosis of active MM as defined by the International Myeloma Working Group (IMWG) criteria.

ii. Subjects must have relapsed or refractory disease after either one of the following:

  1. At least 3 prior regimens, which must have contained an alkylating agent, proteasome inhibitor, and immunomodulatory agent (IMiD) OR
  2. At least 2 prior regimens if "double-refractory" to a proteasome inhibitor and IMiD, defined as progression on or within 60 days of treatment with these agents.

Note: Induction therapy, stem cell transplant, and maintenance therapy, if given sequentially without intervening progression, should be considered as 1 "regimen".

iii. Subjects must be at least 90 days since autologous stem cell transplant, if performed.

iv. Toxicities from prior therapies, with the exception of alopecia or peripheral neuropathy attributable to bortezomib, must have recovered to grade ≤ 2 according to the Common Toxicity Criteria (CTCAE) 4.0 criteria or to the subject's prior baseline.

v. Subjects must have measurable disease per IMWG criteria on study entry, which must include at least 1 of the following:

  1. Serum M-spike ≥ 0.5 g/dL*
  2. 24 hour (hr) urine M-spike ≥ 200mg
  3. Involved serum free light chain (FLC) ≥ 50 mg/L with abnormal ratio
  4. Measurable plasmacytoma on exam or imaging
  5. Bone marrow plasma cells ≥ 20%

    • Note: Patients with IgA myeloma in whom serum protein electrophoresis is deemed unreliable, due to co-migration of normal serum proteins with the paraprotein in the beta region, may be considered eligible as long as total serum IgA level is elevated above normal range.

      b. Melanoma i. Subjects must have a confirmed prior diagnosis of melanoma. ii. Progressed after at least 2 therapy lines. iii. Subjects with BRAF mutant tumors should have received and progressed through, or are intolerant to, BRAF/MEK inhibitor therapy prior to enrollment iv. Patients must have measurable disease per RECIST 1.1 in order to allow assessment of an anti-tumor response.

      c. Synovial Sarcoma or Myxoid/Round Cell Liposarcoma (MRCL) i. Subjects must have a confirmed prior diagnosis of synovial sarcoma or MRCL. ii. Patients with proven metastatic disease or surgically inoperable local recurrence that have failed first line treatment.

iii. Patients must have measurable disease per RECIST 1.1 in order to allow assessment of an anti-tumor response.

  • 2. Provides written, informed consent.
  • 3. Subjects ≥ 18 years of age.
  • 4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
  • 5. Documented NY-ESO-1 expression on tumor tissue.
  • 6. HLA-A*201 positive
  • 7. Subjects of reproductive potential must agree to use acceptable birth control methods, as described in protocol Section 4.3.
  • 8. Adequate vital organ function as defined by:

    1. Serum creatinine ≤ 2.5 or estimated creatinine clearance ≥30 ml/min and not dialysis-dependent.
    2. Absolute neutrophil count ≥1000/μl and platelet count ≥50,000/μl (≥30,000/μl if bone marrow plasma cells are ≥50% of cellularity for MM patients).
    3. Serum glutamic oxaloacetic transaminase (SGOT) ≤ 3x the upper limit of normal and total bilirubin ≤ 2.0 mg/dl (except for patients in whom hyperbilirubinemia is attributed to Gilbert's syndrome).
    4. Left ventricular ejection fraction (LVEF) ≥ 45%. LVEF assessment must have been performed within 8 weeks of eligibility confirmation by physician-investigator.

Exclusion Criteria:

  • 1. Pregnant or nursing (lactating) women.
  • 2. Have inadequate venous access for or contraindications to leukapheresis.
  • 3. Have any active and uncontrolled infection.
  • 4. Active hepatitis B or hepatitis C
  • 5. Human immunodeficiency virus (HIV) infection.
  • 6. Any uncontrolled medical or psychiatric disorder that would preclude participation as outlined.
  • 7. New York Heart Association (NYHA) Class III or IV heart failure, unstable angina, or a history of recent (within 6 months) myocardial infarction or sustained (>30 seconds) ventricular tachyarrhythmias.
  • 8. Received prior gene therapy or gene-modified cellular immunotherapy. Subject may have received, however, non-gene-modified autologous T-cells in association with an anti-myeloma vaccine (e.g., hTERT or MAGEA3) or vaccination against infectious agents (e.g., influenza or pneumococcus) as was performed on our previous studies.
  • 9. Active auto-immune disease, including connective tissue disease, uveitis, sarcoidosis, inflammatory bowel disease, or multiple sclerosis, or have a history of severe (as judged by the principal investigator) autoimmune disease requiring prolonged immunosuppressive therapy.
  • 10. Prior allogeneic stem cell transplant.
  • 11. Prior or active central nervous system (CNS) involvement (e.g. leptomeningeal disease, parenchymal masses) with myeloma. Screening for this (e.g. with lumbar puncture) is not required unless suspicious symptoms or radiographic findings are present. Subjects with calvarial disease that extends intracranially and involves the dura will be excluded, even if cerebrospinal fluid (CSF) is negative for myeloma.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03399448


Contacts
Contact: EmergingMed 855-216-0098 PennCancerTrials@emergingmed.com

Locations
United States, Pennsylvania
University of Pennsylvania Recruiting
Philadelphia, Pennsylvania, United States, 19104
Contact: Emerging Medicine    855-216-0098    PennCancerTrials@emergingmed.com   
Sponsors and Collaborators
University of Pennsylvania
Investigators
Principal Investigator: Edward Stadtmauer, MD University of Pennsylvania

Responsible Party: University of Pennsylvania
ClinicalTrials.gov Identifier: NCT03399448     History of Changes
Other Study ID Numbers: UPCC# 25416; IRB #826672
First Posted: January 16, 2018    Key Record Dates
Last Update Posted: June 20, 2018
Last Verified: June 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Pediatric Postmarket Surveillance of a Device Product: No

Additional relevant MeSH terms:
Multiple Myeloma
Liposarcoma
Sarcoma, Synovial
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Neoplasms, Adipose Tissue
Neoplasms, Connective and Soft Tissue
Sarcoma
Neoplasms, Connective Tissue
Cyclophosphamide
Fludarabine
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents